Cruz AJ, Cruz MA, Tamayo FR, García RE, Alberdi OL, Morín ZJ

Language: Spanish
References: 23
Page:
PDF size: 228.11 Kb.

ABSTRACT

Objective: To evaluate the leakage of radioactivity after intraarticular administration of radioactive suspensions based on Chromium (III) Phosphate as well as the probability of induction of genotoxic effect.
Methods: The suspensions were obtained in line with the published procedure. For the articular leakage evaluation, the radioactive suspensions were intraarticulary administered in rats and rabbits. The radioactivity retention was measured by gamma chamber. A comparison with commercial radiopharmaceutical labeled with 32P was made. The genotoxicity studies determined the frequency of micronuclei formation in the rats´ bone marrow erythrocytes by using 2 doses and 2 time intervals for each preparation.
Results: The radiolabeled suspensions under evaluation showed that the leakage was not significant during 3 weeks (<3% for the suspension labeled with 51Cr and ~5% in the one labeled with 32P) and the advantages of having larger particle preparation were confirmed. For those suspension labeled with 32P and 90Y , no significant difference was seen in the frequency of micronuclei formation for the first time interval, regardless of the administered doses. The micronuclei formation increased for higher doses and at longer time intervals.
Conclusions: The results demonstrated the possibility of the safe use of a of Chromium (III) Phosphate suspension labeled with several radionuclides for the treatment of different joints, in particular the leakage was not significant during 3 weeks and the advantages of having a larger particle radiopharmaceutical was confirmed. For the suspensions labeled with 32P and 90Y micronucleus frequency mildly increased with the time and administered doses.

REFERENCES

1. Clunie G, Ell PJ. A Survey of Radiation Synovectomy in Europe, 1991-1993. Eur. J. Nucl. Med. 1995; 22: 970-6.

2. Kresnik E, Mikosch P, Gallowitsch HJ, Jesenko R, Just H, Kogler D. Clinical Outcome of Radiosynoviorthesis: a meta-Analysis Including 2190 Treated Joints. Nucl. Med. Comun. 2002; 23: 683-8.

3. Kampen WU, Voth M, Pinkert J. Therapeutic status of radiosynoviorthesis of the knee with yttrium [90Y] colloid in rheumatoid arthritis and related indications. Rheumatology. 2007; 46: 16-24.

4. Kampen WU, Matis E, Czech N, Soti Z, Gratz S, Henze E. Serious complications after radiosynoviorthesis. Survey on frequency and treatment modalities. Nuklearmedizin 2006; 45: 2628.

5. Gonca KG, Ömer U, Bülent A. Comparison of extraarticular leakage values of radiopharmaceuticals used for radionuclide synovectomy. Annals of Nuclear Medicine 2006; 20 (3): 1838.

6. Ofluoglu S, Schwameis E, Zehetgruber H, Havlik E, Wanivenhaus A, Schweeger I, Weiss K, Sinzinger H, Pirich Ch. Radiation Synovectomy with 166Ho-Ferric Hydroxide: A First Experience. J. Nucl. Med. 2002; 43: 1489-94.

7. Dunn AL, Busch MT, Wyly JB. Radionuclide Synovectomy for Hemophilic Arthropathy: A Comprehensive Review of Safety and Efficacy and Recommendation for a Standardized Treatment Protocol. J. Thromb. Haemost. 2002; 87(3): 383393.

8. Turkmen C, Ozturk S, Unal SN. The Genotoxic Effects in Lymphocyte Cultures of Children Treated with Radiosynovectomy by Using Yttrium-90 Citrate Colloid. Cancer Biotherapy & Radiopharmaceuticals 2007; 22(3): 393-9.

9. Cruz J, Morín Zorrilla J, Cruz Morales A. Fosfato de Cromo(III) marcado con diferentes radionúclidos para uso en Radiosinoviortesis. Rev. Cub. Farm. 2012; 46(2): 162-72.

10. .Ensayo de biodistribución para el control de calidad de radiofármacos. Procedimiento. Centro de Isótopos. 2004. Reporte No.: DCC.PNO.034.

11. Krishna G, Hayashi M. In vivo rodent micronucleus data in mice and rats. Mutation Research 2000; 453: 155-6.

12. Pandey U, Bapat K, Sarma HD. Bioevaluation of 90Y-labeled particles in animal model of arthritis. Ann. Nucl. Med. 2009; 23: 333-9.

13. Grmek M, Milcinski M, Fettich J. Radiation Exposure of Hemophiliacs After Radiosynoviorthesis with 186Re Colloid. Cancer Biotherapy & Radiopharmaceuticals 2007; 22(3): 417-422.

14. .Soroa VE, del Huerto M, Giannonne C, Caviglia H, Galatros G, Fernández D, Méndez M, Naswetter GG, Nicolini JO Effects of Radiosynovectomy with P-32Colloid Therapy in Hemophilia and Rheumatoid Arthritis. Cancer Biotherapy & Radiopharmaceuticals. 2005; 20(3): 344-8.

15. Szuba A, Shin WS, Straus W and Rockson S. The Third Circulation: Radionuclide Lymphoscintigraphy in the Evaluation of Lymphedemia. J. Nucl. Med. 2003; 44(1): 43-53.

16. Anguileri LJ. In Vivo Distribution of Radioactive Chromic Phosphate: Influence of the Particle Size and Route of Injection. International Journal of Applied Radiation and Isotopes». 1965; 16: 623-630.

17. Anghileri LJ, Marques R. New Colloidal Chromic Radiophosphate for Local Irradiation of the Central Nervous System. Int. J. Appl. Radiat. Isot. 1967; 18: 97-100.

18. Noble J, Jones AG, Davis MA, Sledge CB, Kramer RI, Livni E. Leakage of Radioactive Particle Systems from a Synovial Joint Studied with a Gamma Camera. Its Application to Radiation Synovectomy. J. Bone Joint Surg. Am. 1983; 65 (3): 381-9.

19. Fernández-Palazzi F, Caviglia H. On the Safety of Synoviorthesis in Haemophilia. 2001; 7 (2): 50-3.

20. Vuorela J, Sokka T, Pukkala E. Does yttrium radiosynovectomy increase the risk of cancer in patients with rheumatoid arthritis? Ann Rheum Dis 2003; 62: 2513.

21. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005; 3: 15412.

22. Voth M, Klett R, Lengsfeld P. Biological dosimetry after Y-90 citrate radiosynoviorthesis. Nuklearmedizin. 2006; 45(5): 223-8

23. Turkmen C. «Safety of Radiosynovectomy in Hemophilic Synovitis: it is Time to Re-evaluate! « J of Coag. Disorders 2009; 1(1): 29-36.